Director/PCA Shareholding
Summary by AI BETAClose X
Dr. Martens plc (the 'Company')
Notification of Transactions by a Director and Person Closely Associated
The Company announces that it has been notified of the following transactions in the Company's Ordinary 1p shares (the 'shares') undertaken by a director / person discharging managerial responsibility ('PDMR') and a person closely associated with them ('PCA'):
- On 1 September 2025, Giles Wilson, Chief Financial Officer, purchased 105,838 shares in his ISA at a price of £0.91377 per share, having sold 105,785 shares at a price of £0.8965 per share.
- On 1 September 2025, Katie Wilson, a PCA of Giles Wilson, purchased 30,019 shares in her ISA at a price of £0.911447 per share, having sold 30,000 shares at a price of £0.910823 per share.
Following these transactions, which entail the movement of holdings into ISAs, Giles's overall beneficial interest in the Company's shares is 260,193 Ordinary Shares.
The relevant notifications, set out below, are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name |
Giles Wilson |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
PDMR (Chief Financial Officer) |
||||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Dr. Martens plc |
||||||
|
b) |
LEI |
213800QPT8YM6NQZPH28 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of GBP 0.01
|
||||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
|
N/A - single transaction |
||||||
|
e) |
Date of the transaction |
1 September 2025 |
||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name |
Giles Wilson |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
PDMR (Chief Financial Officer) |
||||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Dr. Martens plc |
||||||
|
b) |
LEI |
213800QPT8YM6NQZPH28 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of GBP 0.01
|
||||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
|
N/A - single transaction |
||||||
|
e) |
Date of the transaction |
1 September 2025 |
||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name |
Katie Wilson |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Person Closely Associated with Giles Wilson, Chief Financial Officer and PDMR |
||||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Dr. Martens plc |
||||||
|
b) |
LEI |
213800QPT8YM6NQZPH28 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of GBP 0.01
|
||||||
|
b) |
Nature of the transaction |
Purchase of Ordinary Shares |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
|
N/A - single transaction |
||||||
|
e) |
Date of the transaction |
1 September 2025 |
||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a) |
Name |
Katie Wilson |
||||||
|
2 |
Reason for the notification |
|||||||
|
a) |
Position/status |
Person Closely Associated with Giles Wilson, Chief Financial Officer and PDMR |
||||||
|
b) |
Initial notification/Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a) |
Name |
Dr. Martens plc |
||||||
|
b) |
LEI |
213800QPT8YM6NQZPH28 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of GBP 0.01
|
||||||
|
b) |
Nature of the transaction |
Sale of Ordinary Shares |
||||||
|
c) |
Price(s) and volume(s) |
|
||||||
|
d) |
Aggregated information
|
N/A - single transaction |
||||||
|
e) |
Date of the transaction |
1 September 2025 |
||||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
||||||
For further information, please contact:
Paul Rolling, Head of Secretariat
+447584243562
Bethany Barnes, Director of Investor Relations
+447825187465
ENDS
About Dr. Martens
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. "Docs" or "DMs" were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned "1460" boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. Further information can be found at https://www.drmartensplc.com/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 3 hours ago Oxford Nanopore Technologies
- 4 hours ago AVI Global Trust
- 4 hours ago LSL Property Services
- 4 hours ago Bluebird Merchant Ventures (DI)
- 4 hours ago Power Probe PLC